CSI third quarter revenues increase 5 percent to $21 sildenafil zulassung deutschland.

CSI third quarter revenues increase 5 percent to $21.2 million Cardiovascular Systems, Inc. , a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2012 sildenafil zulassung deutschland . CSI’s revenues in the third quarter rose to $21.2 million, an 8 % increase over the next quarter of fiscal 2012, and a 5 % gain over revenues of $20.2 million in the third quarter of last fiscal year.


Dr. Sodickson also pointed out that the techniques implemented in his group’s study could be used to identify higher risk sufferers who might reap the benefits of ‘enhanced radiation protection initiatives’. This statement is of particular curiosity because it appears to indicate better radiation safety is available – – although obviously not being routinely used. Various other scientists have got previously urged restraint in using CT scans too often and have sounded alarms over the radiation exposure associated with the technology. For example, in 2007, composing in The New England Journal of Medicine, David J.